Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ALKS-5461
ALKS-5461
Alkermes shares take another hit as the FDA shakes its head — again — on a weak case for '5461
Endpoints
Fri, 02/1/19 - 10:41 pm
Alkermes
FDA
ALKS-5461
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
Fri, 12/21/18 - 12:10 pm
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Alkermes Depression Drug Faces Long Odds After FDA Advisors Say No
Xconomy
Thu, 11/1/18 - 07:30 pm
Alkermes
FDA
advisory panels
ALKS-5461
major depressive disorder
FDA Now Accepts Alkermes Application It Rejected Two Weeks Ago
CP Wire
Mon, 04/16/18 - 09:05 am
Alkermes
ALKS-5461
major depressive disorder
FDA
FDA Now Accepts Alkermes Application It Rejected Two Weeks Ago
Mon, 04/16/18 - 08:52 am
Alkermes
ALKS-5461
Alkermes' Bad News Could Be Good News for Johnson & Johnson
Motley Fool
Wed, 04/4/18 - 10:07 pm
Alkermes
JNJ
ALKS-5461
esketamine
major depressive disorder
The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
TheStreet.com
Thu, 03/9/17 - 11:25 am
FDA
drug approvals
Alkermes
ALKS-5461
CytRx
aldoxorubicin
Dynavax Technologies
HEPLISAV-B
Intra-Cellular Therapies
ITI-007
Novan
SB204
Portola Pharmaceuticals
betrixaban
PTC Therapeutics
ataluren
Rigel Pharmaceuticals
fostamatinib
TG Therapeutics
ublituximab
Alkermes slammed as top depression drug fails two PhIIIs
Fierce Biotech
Thu, 01/21/16 - 05:42 pm
Alkermes
ALKS-5461
clinical depression
clinical trials